Higher Scientific Officer - Drug Discovery Biology, Centre for Protein Degradation
External Advertising End Date:
- Higher Scientific Officer - Drug Discovery Biology, Centre for Protein Degradation
Key Information
Salary:£39,805 - £49,023 per annum. Commencement on the salary range is subject to comparable skills and experience. Future progression is based on annual performance review.
Reporting to:Dr Agnieszka Konopacka
Duration of Contract:Fixed Term for 2 years (in the first instance)
Hours per week:35 hours per week (Full Time)
Closing Date:03 April 2025
We will be reviewing the applications on an ongoing basis. Therefore, we advise you to submit your application without delay.
We are seeking to recruit a Higher Scientific Officer within the Induced Proximity Therapeutics (IPT) Team in the ICR Centre for Protein Degradation to support our molecular glue and PROTAC drug discovery projects and expand induced proximity technology. The IPT team focuses on three main areas of research:
- Screening, profiling and molecular mechanism of action of molecular glue and PROTAC degraders
- Novel E3 ligase biology and ligand discovery
The successful candidate will work in a multidisciplinary team and play a key role in target validation, developingin vitroand cell-based assays, and pharmacological characterization of novel molecular glue degraders and PROTACs, but may also contribute to other activities.
About You
The successful candidate:
- Will be a strong team player who is technically minded and passionate about science and cancer drug discovery
- Will hold a first degree, and preferably a PhD, in biological science or biochemistry
- Will have experience in cancer biology/target validation, genetic manipulation techniques,in vitroand cell-based assay development, and pharmacological compound profiling
Experience in targeted protein degradation will be a significant advantage.
Department/Directorate Information
This position will be based in the ICR's Centre for Protein Degradation, a part of the Centre for Cancer Drug Discovery (CCDD) specializing in developing novel drug modalities that re-wire tumor cells' signaling by targeted degradation of key oncogenic drivers. Our experienced biologists work closely with medicinal chemists, biophysicists, computational scientists, oncology specialists, and physicians on discovering new medicines - molecular glue degraders and PROTACs - using innovative screening platforms and characterizing their mechanisms of action, as well as expanding the repertoire of novel degradable drug targets and E3 ligases (enzymes that mediate protein degradation). Our research provides a nucleus for the academics and pharmaceutical industry to explore the therapeutic potential of targeted protein degradation from laboratory hypothesis-testing to early clinical trials, for the benefit of cancer patients.
What We Offer
- A dynamic and supportive research environment in one of the successful academic cancer drug discovery centres in the UK
- Access to state-of-the-art facilities and professional development
- Collaboration with leading drug discovery and oncology scientists
- Competitive salary and pension
To learn more about this role, please download the attached job pack. For informal inquiries, please contact Dr Agnieszka Konopacka, Group Leader, Induced Proximity Therapeutics, Centre for Protein Degradation via email: .
About The Institute of Cancer Research
Why work for us?
As a member of staff, you'll have exclusive access to a range of staff benefits.
The ICR is committed to supporting overseas applicants applying for roles, please click here to find out further information.
The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here.
We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview. However, we particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles.
#J-18808-Ljbffr
